Loading stock…

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Madrigal Pharmaceuticals, Inc.

MDGLMarket cap $11BPrice $496.4

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops treatments for liver disease, and just made history with Rezdiffra — the first FDA-approved drug for NASH, a condition affecting over 20 million Americans with zero prior treatment options.

In Bastion Portfolios?

52W Return+13%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)+59%10

Rev CAGR (3y)+43%10

Rev CAGR (5y)+37%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+20%5

EPS Growth Y+3+173%10

Quality

Margins

EBIT Margin-25%1

Net Income Margin-25%1

Free Cash Flow Margin-16%2

Debt

Net Debt/EBITDAna–

Efficiency

ROE-53%1

ROA-29%1

Earnings Stabilityna–

GEAR+WEAK21

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)145

P/BV21.91

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-1.8%2

Dividend Yieldna–

Momentum

Short term

1 month return-8%3

3 month return-9%4

YTD return-15%3

Mid term

Price vs 52wHigh81%5

1 year return+14%6

Long term

3 year return+252%9

5 year return+514%10

Risk Shield

Price Risk

Beta0.39

Volatility43%4

Free Cash Flow

Free Cash Flow Margin-16%2

Free Cash Flow Yield-1.8%2

Quality

ROCE-38%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

GROWTH RATING↗

STRONG84 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+59%10

Revenue, next 3Y, CAGR+43%10

Revenue, next 5Y, CAGR+37%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+173%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 84% of companies worldwide.

Revenue is set to grow 43%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 43%/yr from here.

The runway holds up: revenue is set to grow 37%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE56 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return-9%4

YTD return-15%3

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return+14%6

3-year return+252%9

5-year return+514%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +252% over three years and +514% over five, ahead of 90% of the market.

WATCH

It's up 14% over the past year, but 19% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over three months (-9%).

WEAKNESSES

The stock is underperforming over the past month (-8%) and so far this year (-15%).

BOTTOM LINE

Long-Term Winner, Cooling Off

Multi-year returns are elite even though the latest weeks are quieter. Often a quality compounder taking a breather rather than breaking down. The one thing to watch: the stock is underperforming over the past month and so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Madrigal Pharmaceuticals. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GROWTH RATING↗

STRONG84 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+59%10

Revenue, next 3Y, CAGR+43%10

Revenue, next 5Y, CAGR+37%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+173%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 84% of companies worldwide.

Revenue is set to grow 43%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 43%/yr from here.

The runway holds up: revenue is set to grow 37%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE56 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return-9%4

YTD return-15%3

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return+14%6

3-year return+252%9

5-year return+514%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +252% over three years and +514% over five, ahead of 90% of the market.

WATCH

It's up 14% over the past year, but 19% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over three months (-9%).

WEAKNESSES

The stock is underperforming over the past month (-8%) and so far this year (-15%).

BOTTOM LINE

Long-Term Winner, Cooling Off

04Value

Are you paying a fair price for it?

Stop guessing on Madrigal Pharmaceuticals. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community